IO Biotech is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on its T-win technology platform. Co.'s product candidates are designed to induce the immune system to simultaneously target and disrupt various pathways that regulate tumor-induced immunosuppression. Co.'s main product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. In addition to IO102, IO103 and IO112, Co. is evaluating additional candidates that have potential for use in solid tumors. We show 6 historical shares outstanding datapoints in our IOBT shares outstanding history coverage, used to compute IOBT market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing IOBT market cap history over the course of time is important for investors
interested in comparing IOBT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of IOBT versus a peer is one thing; comparing
IOBT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like IOBT can fluctuate over the course of history.
With this page we aim to empower investors researching IOBT by allowing them to research the IOBT market cap history. |
Free IOBT Email Alerts:
Video: The Importance of Market Cap
